Welcome to our dedicated page for Lantheus Holdings news (Ticker: LNTH), a resource for investors and traders seeking the latest updates and insights on Lantheus Holdings stock.
Lantheus Holdings, Inc. (NASDAQ: LNTH) is a leading radiopharmaceutical-focused company, dedicated to the development, manufacture, and commercialization of innovative diagnostic imaging agents and products. Headquartered in North Billerica, Massachusetts, and with additional offices in Puerto Rico and Canada, Lantheus has been a pivotal player in the medical imaging industry for over 65 years.
The company's primary subsidiary, Lantheus Medical Imaging, Inc. (LMI), specializes in diagnostic imaging solutions primarily for cardiovascular diseases. Key products include the echocardiography contrast agent DEFINITY® Vial, the technetium-based generator TechneLite®, and the inhaled radiopharmaceutical imaging agent Xenon Xe 133 Gas for lung imaging.
Lantheus is organized into three main business units: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostics focuses on products that assist healthcare professionals in detecting and monitoring diseases, particularly in cardiology. Radiopharmaceutical Oncology offers diagnostics and therapeutic solutions that help healthcare providers manage cancer. Through its Strategic Partnerships, Lantheus collaborates to advance precision medicine using biomarkers and digital solutions.
Recent achievements include strategic transactions to enhance their pipeline for neuroendocrine tumors and prostate cancer. Lantheus has partnered with Perspective Therapeutics, which has developed a best-in-class alpha therapy platform, enabling Lantheus to expand its pipeline into promising alpha therapies.
Financially, Lantheus has shown robust performance. The company reported record revenues of $1.3 billion for the full year 2023, marking a 38.6% increase from 2022. This growth was driven by the successful commercialization of innovative products and strategic acquisitions.
In the Radiopharmaceutical Oncology space, the company’s Abbreviated New Drug Application (ANDA) for Lutetium Lu 177 Dotatate has been accepted by the FDA. This product is intended for treating somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Lantheus continues to drive innovation and growth through its robust pipeline and strategic collaborations. Recent leadership changes have positioned the company for its next phase of growth, with Brian Markison taking over as CEO from March 2024, following the successful tenure of Mary Anne Heino.
For ongoing updates and more information, visit their website at www.lantheus.com.
Lantheus Holdings has announced key management promotions, with Paul Blanchfield becoming Chief Operating Officer and Dottie Barr promoted to Senior Vice President, Manufacturing and Technical Operations. Effective immediately, these changes aim to leverage their expertise for enhanced strategic execution and patient outcomes. Blanchfield, previously Chief Commercial Officer, is recognized for his role in launching the PSMA PET imaging agent for prostate cancer, while Barr has successfully led manufacturing and supply chain improvements despite pandemic challenges.
Lantheus Holdings presented preliminary results of the PD-L1 Expression in Cancer (PECan) study at the SNMMI Annual Meeting. The study focuses on NM-01, a technetium 99m SPECT/CT imaging agent, which aims to assess PD-L1 expression in cancer cells. Preliminary findings indicate that NM-01 can identify patients likely to respond to checkpoint inhibitor therapies, particularly in non-small cell lung cancer (NSCLC). The study included 10 patients, revealing significant insights into PD-L1 expression and treatment response, suggesting NM-01 could enhance patient selection and monitoring in clinical settings.
Lantheus Holdings presented results at the SNMMI Annual Meeting, showcasing the effectiveness of PYLARIFY AI, an FDA-cleared AI platform for PSMA PET/CT scans in prostate cancer. The study highlighted its ability to enhance lesion detection and quantitative assessment compared to manual readings, with significant improvements in diagnostic accuracy and efficiency. The findings reaffirm Lantheus's commitment to integrating AI in oncology, potentially transforming prostate cancer management and improving patient outcomes.
Lantheus Holdings (NASDAQ: LNTH) announced that Mary Anne Heino, CEO, and Bob Marshall, CFO, will present at the Jefferies Healthcare Conference on June 9 at 11:00 a.m. ET. The event will take place in New York City, showcasing the company's commitment to innovative imaging diagnostics and therapeutics. Investors can access a live webcast of the presentation on the company’s website, with a replay available for 30 days post-event. Lantheus is a leader in advanced medical imaging solutions, aiming to enhance patient care through its diverse product portfolio.
Lantheus Holdings, Inc. (NASDAQ: LNTH) announced key presentations at the 2022 SNMMI Meeting in Vancouver, scheduled for June 11-14, 2022. The event will feature oral presentations on two significant imaging agents: PYLARIFY® (piflufolastat F18) for prostate cancer and PYLARIFY AI™, an AI platform for PSMA PET imaging. PYLARIFY's efficacy will be discussed concerning androgen deprivation therapies, while PYLARIFY AI™ will highlight a Phase III study aimed at rapid lesion detection. These advancements reflect Lantheus's commitment to innovative diagnostics and therapeutics in oncology.
Lantheus Holdings has announced its Inaugural Investor Day, scheduled for May 17, 2022, where it will outline its long-term growth strategy and financial targets. The event will feature updates from the management team on key commercial products and development assets. CEO Mary Anne Heino expressed enthusiasm for providing insights into their business and growth strategies aimed at delivering long-term value for patients and shareholders. The live webcast will be accessible for replay post-event.
Lantheus Holdings (NASDAQ: LNTH) released findings from a retrospective study analyzing the use of its PYLARIFY® AI in monitoring treatment response in prostate cancer patients. The study demonstrated that changes in PSMA scan indices correlated significantly with prostate-specific antigen (PSA) responses post-androgen deprivation therapy. Patients exhibited a 97% average decline in PSA levels, paired with significant reductions in PSMA indices in lymph nodes and bone. These results suggest PYLARIFY AI may enhance the quantification of disease burden and response to therapy in prostate cancer management.
Lantheus Holdings announced the initiation of a Phase 2 trial for NM-01, a technetium-99m SPECT imaging agent aimed at assessing PD-L1 expression in non-small cell lung cancer (NSCLC). The PELICAN trial will evaluate NM-01's ability to identify responders to checkpoint inhibitor therapies compared to traditional immunohistochemistry methods. Conducted in partnership with NanoMab Technology at King’s College London, this trial seeks to improve patient selection for treatment and offers a non-invasive alternative to biopsies. The outcome could enhance treatment efficacy and minimize unnecessary side effects.
Lantheus Holdings has announced updates from the National Comprehensive Cancer Network (NCCN) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) regarding the use of PYLARIFY® (piflufolastat F 18) for prostate cancer. The guidelines now include PYLARIFY as a recommended agent for patient selection in PSMA-targeted radioligand therapy. This follows PYLARIFY's FDA approval and aims to enhance access to targeted treatments for patients with advanced prostate cancer.
NORTH BILLERICA, Mass., May 10, 2022 – Lantheus Holdings (NASDAQ: LNTH) announced that President and CEO Mary Anne Heino, along with CFO Bob Marshall, will present at the UBS Global Healthcare Conference. The presentation is scheduled for 8:30 a.m. ET on May 24, 2022, in New York. Investors can access a live webcast through the Company’s website, with a replay available for 30 days post-event. Lantheus is known for its innovative imaging diagnostics and AI solutions aimed at serious medical conditions.
FAQ
What is the current stock price of Lantheus Holdings (LNTH)?
What is the market cap of Lantheus Holdings (LNTH)?
What does Lantheus Holdings, Inc. specialize in?
What are some key products of Lantheus?
Where is Lantheus Holdings headquartered?
What are the core business units of Lantheus?
Who is the current CEO of Lantheus Holdings?
What recent achievements has Lantheus accomplished?
What financial growth did Lantheus achieve in 2023?
What is the significance of DEFINITY® Vial?
What types of diseases does Lantheus focus on in their diagnostics?
How does Lantheus contribute to precision medicine?
